42nd week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210322457 | TREATMENT AND DIAGNOSIS OF OCULAR SURFACE DISORDERS - The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates/debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin/conjunctival keratinization, corneal neovascularization/pannus, subconjunctival fibrosis, and herpetic eye disease. The present invention also provides a method for diagnosing or monitoring an ocular surface disease. | 2021-10-21 |
20210322458 | METHODS AND COMPOSITIONS FOR TREATMENT OF BURNS, JOINT PAIN, AND FUNGAL INFECTIONS - In one aspect, the disclosure relates to pharmaceutical compositions for treatment of burns, e.g., sunburns, methods of making same, and methods of treating burns using same. The disclosure, in another aspect, relates to pharmaceutical compositions for treatment of joint pain, methods of making same, and methods of treating joint pain using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. | 2021-10-21 |
20210322459 | PROPHYLACTIC USE OF INULIN AGAINST SINUSITIS - The present invention relates to an inulin composition comprising GF | 2021-10-21 |
20210322460 | INJECTABLE MONOPHASE HYDROGELS - An injectable monophase hydrogel is provided that is made of a reaction mixture of hyaluronic acids having different molecular weights. | 2021-10-21 |
20210322461 | METHOD OF CROSS-LINKING COLLAGEN - A method of cross-linking collagen comprises generating reactive species from a non-thermal plasma and delivering the reactive species to a collagen-containing target to induce collagen cross-linking. In a specific embodiment, the reactive species can be a reactive oxygen species, for example singlet oxygen. A method of cross-linking collagen comprises generating reactive oxygen species from a non-thermal plasma and delivering the reactive species to a collagen-containing target to induce collagen cross-linking, wherein the non-thermal plasma is generated from a non-flammable gas medium comprising an inert buffer gas, the reactive oxygen species is selected from the group consisting of a superoxide ion radical, hydroxyl radical, peroxide, hydrogen peroxide, organic peroxide, or a combination thereof, and the collagen-containing target is corneal tissue and wherein the collagen cross-linking induces cross-linking within and between collagen fibers in the corneal tissue. | 2021-10-21 |
20210322462 | WOUND PREVENTION AND/OR TREATMENT AND RELATED COMPOUNDS, MATRICES, COMPOSITIONS, METHODS AND SYSTEMS - Wound healing matrices, compounds, compositions, methods and systems comprising one or more chlorates, one or more chlorites, one or more antibiotics, one or more other antimicrobials, and/or one or more wound healing agents. | 2021-10-21 |
20210322463 | METHOD FOR ACCELERATED TISSUE PENETRATION OF COMPOUNDS INTO BRAIN - Disclosed is a method of increasing the rate of delivery of an active compound or agent to the brain across the blood brain barrier of a subject. In one aspect, the disclosure provides an accelerated method of providing an active compound to a targeted region of the brain of a subject, served by the cerebral medial artery, the method comprising: administering a sub-anesthetic dose of xenon as an inhalant to the subject; and administering an efficacious amount of the active compound to the bloodstream of the subject, the active compound reaching the targeted region of the brain in less time relative to a time it takes to reach the targeted region without xenon administration. | 2021-10-21 |
20210322464 | METHOD OF TREATING AND PREVENTING CORONAVIRUS DISEASE 19 (COVID-19) USING A SELENIUM ADMINISTRATION - The present invention provides methods for treatment and prevention of Coronavirus Disease 2019 (COVID-19) and any clinical presentations associated with it including Acute Respiratory Distress Syndrome (ARDS), Severe Inflammatory Response Syndrome (SIRS), and/or any state corresponding to a severe acute attack of an inflammatory pathology causing an exacerbation of cytokine storm associated with unregulated oxidative, endoplasmic reticulum, and inflammatory stress mediated cytotoxic effects following the infection with the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) with at least a pharmacologically acceptable trace element, Selenium (Se) containing molecule, or compound, or drug, or injection, or intravenous infusion. This is achieved by administering to a subject, a therapeutically effective amount of at least a pharmacologically acceptable molecule containing Se at an initial high dose followed by reduced, continuous dosing in subsequent treatment so as to employ its antioxidant, cytokine-modulating, antiviral, immune-enhancing, anti-apoptotic, and anticoagulant properties for the treatment and prevention of COVID-19. | 2021-10-21 |
20210322465 | MAGNESIUM-CONTAINING FORMULATION AND USES THEREOF - The present invention, in some embodiments thereof, relates to nutrition and, more particularly, to magnesium and L-Carnitine containing formulations which enhance the effect of exercise on fat metabolism, and which are useful, for example, in the treatment of liver conditions, such as fatty liver disease, chronic liver disease, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), hepatitis, fibrosis, cirrhosis and non-alcoholic steatohepatitis (NASH). | 2021-10-21 |
20210322466 | METHODS AND COMPOSITION FOR IMPROVED ANTISEPSIS - Disclosed are devices and methods for treating and disinfecting a surface that is also useful for the treatment of patients. Compositions, including antiseptic compositions, that can be used for the methods are also disclosed. In particular, invention provides an improved antiseptic with improved efficacy against COVID-19. One benefit of the disclosed methods and compositions is that it is effective even when used for very short contact times. The composition of the invention comprises an antiseptic and a cellulosic polymer. | 2021-10-21 |
20210322467 | METHOD OF PREVENTING OR TREATING VIRAL INFECTIONS - A method of treating or preventing a disease or condition caused (at least in part) by, or related to, a viral infection in a patient, comprising administering to said patient a pharmaceutical composition comprising, in certain embodiments, | 2021-10-21 |
20210322468 | A NANOPARTICLE FOR RADIATION PROTECTION - A nanoparticle for radiation protection is provided. The nanoparticle for radiation protection comprises a first metal oxide nanoparticle. The nanoparticle for radiation protection may further comprise a second metal oxide layer formed on a surface of the first metal oxide nanoparticle. The nanoparticle for radiation protection may have a polar interface between the first metal oxide nanoparticle and the second metal oxide layer. | 2021-10-21 |
20210322469 | ZINC AND COPPER FOR THE PROPHYLAXIS AND TREATMENT OF COVID-19 - This disclosure describes methods for prophylaxis and treatment of coronavirus in vulnerable populations and infected individuals. The methods include the administration of zinc and in some embodiments copper. In some embodiments, an amount of zinc is administered sufficient to raise serum zinc levels to 60 μg/dL. In some aspects, the coronavirus is the SARS-CoV-2 virus and/or the infection is COVID-19. | 2021-10-21 |
20210322470 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS - An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period. | 2021-10-21 |
20210322471 | IN VIVO USE OF MODIFIED CELLS OF LEUKEMIC ORIGIN FOR ENHANCING THE EFFICACY OF ADOPTIVE CELL THERAPY - The present disclosure provides in vivo methods which employ modified cells of leukemic origin to enhance the efficacy of adoptive cell therapy. | 2021-10-21 |
20210322472 | Use of Lentivector-Transduced T-RAPA Cells for Amelioration of Lysosomal Storage Disorders - The present disclosure provides methods of treating lysosomal storage disorders. The method comprises producing vector-transduced T-Rapa cells that express a transgene of interest and administering the cells to a patient in need thereof. | 2021-10-21 |
20210322473 | MODIFIED T CELLS AND METHODS OF THEIR USE - The technology described herein relates to modified T cells and their use in immunotherapeutic methods. In various examples, the T cells are modified so as to decrease or eliminate CD3ζ, TRAC, and/or TRBC expression. | 2021-10-21 |
20210322474 | MODULATION OF APOPTOSIS SUSCEPTIBLE CELLS - Provided are methods for producing a population of cells enriched with non-activated/non-mature cells, in particular non-activated/non-mature T and/or B cells, optionally genetically modified T and/or B cells. The method includes contacting a heterogeneous population of mammalian cells with an apoptosis inducing ligand, wherein said contacting induces apoptosis of active/mature cells while non active/mature cells remain resistant to the apoptotic signal. Further provided are therapeutic uses of the enriched cell populations. | 2021-10-21 |
20210322475 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The invention provides combination therapies for treating cancer comprising compositions and methods for γδ T cell immunotherapy in combination DDR inhibitors, including but not limited to PARP inhibitors. Preferably, the combination of γδ T cell immunotherapy and PARP inhibitors for the treatment of cancer further includes combinations with other immunotherapies such as immune checkpoint (ICP) blockade therapy and/or DNA damaging agents such as cytotoxic chemotherapeutic agents. Preferably, when the combination of γδ T cell immunotherapy and DDR inhibitor therapy further include chemotherapeutic agents, the γδ T cells are genetically modified to impart resistance to that chemotherapeutic agent. | 2021-10-21 |
20210322476 | COMPOSITIONS AND METHODS FOR IMMUNOSUPPRESSION - Provided herein is are regulatory T cells (Tregs) capable of specifically suppressing immune response against a donor alloantigen or an autoantigen, compositions thereof, and methods for producing the same. Optionally, the Tregs are used in a population including natural killer (NK) cells. Also described are related methods for using the Tregs or mixed population of Tregs and NK cells, including for promoting allograft acceptance in a transplant recipient and treating autoimmune disorders in a subject. The Tregs or mixed population of Treg and NK cells are derived from the subject's blood cells and can reduce or replace the use of broad-acting immunosuppressants. | 2021-10-21 |
20210322477 | ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS - Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer. | 2021-10-21 |
20210322478 | PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-10-21 |
20210322479 | METHODS FOR PREPARING PLATELET PRODUCTS - Provided herein are improved processes for preparing and treating platelet products. The methods are useful in the efficient preparation of platelet products with desirable characteristics, including pathogen inactivated platelet products. | 2021-10-21 |
20210322480 | Platelet-Rich Plasma Compositions and Related Methods - An antiviral composition is provided. The antiviral composition includes a platelet-rich plasma composition. Methods of treatment and initiating passive immunity for viral infections are also provided. | 2021-10-21 |
20210322481 | Compositions Comprising Milk Fat Globules and Methods of Making Same - Compositions including anti-viral compositions, therapeutic compositions, sunscreen compositions, skin treatment compositions, anti-aging compositions, and methods of making the same, are provided. Each composition includes milk fat globules (MFG) and may contain one or more agents encapsulated by the MFG. The unique nature of MFG provides an intact mammalian membrane containing proteins, glycoproteins, and carbohydrates found in mammary cells. By treating an infected patient with MFG, the MFG serve as a surrogate cell and interact with enveloped viruses, such as the COVID-19 coronavirus, the Herpes virus, and the Epstein Barr Virus, rendering them non-infectious. MFG derived from mammals can also be used to deliver pharmaceutical materials into an animal body such that the pharmaceutical materials bypass the venous blood and enter directly into the animal's lymphatic system. MFG allow the delivery of materials orally that could not heretofore have been delivered efficiently. | 2021-10-21 |
20210322482 | STEM CELL-PRODUCED MICROVESICLES FOR TREATING TENDON PATHOLOGIES - Microvesicles produced by stem cells grown on a silk scaffold for enhancing stem cell self-renewal/proliferation and promoting tenogenesis in damaged tendons, and their use in tendon wound repair and tendinopathy treatment. Also provided are compositions containing the microvesicles and devices for obtaining them. | 2021-10-21 |
20210322483 | CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPY - A composition comprising cell-derived particles presenting heterologous CD24, wherein the cell is a non-cancerous cell and wherein the composition is substantially devoid of intact cells is disclosed. Methods of producing the cell-derived particles and methods of using the cell-derived particles in treatment of cytokine storm syndrome, tissue injury associated with the inflammation and Coronavirus infection are also disclosed. | 2021-10-21 |
20210322484 | MACROMOLECULAR CLUSTERS OF CARDIAC STEM CELLS AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, provided are macrocellular structures or artificially configured plurality of cells, the so-called “cardioclusters” as provided herein, comprising: a core region or cluster: comprising a plurality of first cardiac stem cells or cardiac progenitor cells; and a second region or a peripheral region positioned at least partially surrounding the outer surface of the core region or cluster, or at least partially around the core region or cluster, comprising a plurality of second cardiac stem cells; and methods for making and using them. In alternative embodiments, the second cardiac progenitor cells are cardiac progenitor cells or cardiac stem cells, mesenchymal stem cells or mesenchymal progenitor cells, or endothelial progenitor cells or endothelial stem cells. | 2021-10-21 |
20210322485 | MITOCHONDRIAL AUGMENTATION THERAPY WITH STEM CELLS ENRICHED WITH FUNCTIONAL MITOCHONDRIA - The present invention provides stem cells enriched with healthy functional mitochondria, and therapeutic methods utilizing such cells for the alleviation of debilitating conditions, including aging, and age-related diseases as well as the debilitating effects of anti-cancer therapies in subjects in need thereof. | 2021-10-21 |
20210322486 | Coral Composite Extract, Composition Including The Same And Method Of Producing The Same - The present invention relates to a coral composite extract, a composition including the same and a method of producing the same. The coral composite extract includes at least two briarane-type diterpenoid compounds from corals of | 2021-10-21 |
20210322487 | PRODUCTION METHOD OF NASAL DROP COMPOSITION, AND NASAL DROP COMPOSITION - Provided are: a method for producing a nasal drop composition suitable for treatment or prevention of a disease or symptom in the nasal cavities; and a nasal drop composition produced by the production method. The nasal drop composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the nasal drop composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and | 2021-10-21 |
20210322488 | Treatment Methodology for the Prevention and Control of Viral Infections - A treatment methodology for the prevention and control of viral infections by administering an anti-viral composition having organotrophic archaea microorganisms, a carrier substance and an activating liquid, characterized in that the archaea microorganisms, when present in human or animal, weaken or destroy a virus upon contact. The anti-viral composition is administered either intraorally or intranasally. | 2021-10-21 |
20210322489 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS - The present invention relates to | 2021-10-21 |
20210322490 | NOVEL STRAINS HAVING EFFECTS OF PREVENTING OR TREATING CANCERS - The present invention relates to a novel | 2021-10-21 |
20210322491 | BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS - This invention relates to new uses of | 2021-10-21 |
20210322492 | PROBIOTIC STRAINS AND USES THEREOF - The present invention pertains to a probiotic comprising a generally recognized as safe (GRAS) microbiological organism, which GRAS microbiological organism comprises a food-grade expression vector, which vector comprises in functional linkage a nucleic acid sequence encoding for a soluble form of Amuc_1100 or a functionally equivalent fragment of said soluble form of Amuc_1100, wherein said GRAS microbiological organism is capable of expressing and secreting said soluble form of Amuc_1100 or said fragment thereof, as further defined in the claims. Methods for treating a disease in a patient, comprising oral administration of the probiotic as defined herein are also described, as well as methods of preparing the probiotic disclosed herein. | 2021-10-21 |
20210322493 | HUMAN-DERIVED LACTOBACILLUS FERMENTUM MG4231 OR LACTOBACILLUS FERMENTUM MG4244 STRAIN HAVING ANTI-OBESITY ACTIVITY, AND COMPOSITION COMPRISING SAME - The present invention relates to: human-derived | 2021-10-21 |
20210322494 | NOVEL LACTOCOCCUSGARVIEAE BACTERIOPHAGE LAC-GAP-3 AND USE THEREOF IN INHIBITING PROLIFERATION OF LACTOCOCCUSGARVIEAE BACTERIA - The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcusgarvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcusgarvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient. | 2021-10-21 |
20210322495 | ZIKA VIRUS TREATMENT OF CD24-POSITIVE TUMORS AND DISEASES ASSOCIATED WITH ABNORMAL T CELL ACTIVATION AND TREATING OR PREVENTING ZIKA VIRUS INFECTIONS - CD24-positive malignant and benign tumors are treated by administration of a naturally occurring or modified oncolytic Zika virus. Diseases associated with abnormal T cell activation or T cell-mediated autoimmunity, wherein CD24 expression is increased, are also expected to be treated by administration of a naturally occurring or modified oncolytic Zika virus. Also contemplated are compounds and methods for treating and/or preventing Zika virus infection in a subject. | 2021-10-21 |
20210322496 | PHARMACEUTICAL COMPOSITION OR HEALTH FOOD FOR TREATING AND/OR ALLEVIATING NERVOUS DISEASES - A method for treating and/or alleviating nervous diseases is provided. The method for treating and/or alleviating nervous diseases includes: administering an effective amount of a water extract of a plant of Gracilariaceae or a ferment thereof to a subject in need thereof to treat and/or alleviate a nervous disease thereof, wherein the ferment of the water extract of a plant of Gracilariaceae is a lactic acid bacteria ferment. | 2021-10-21 |
20210322497 | Method of Fermenting Soybeans or other Oil Crops by Edible and Medicinal Fungi - The disclosure discloses a method of fermenting soybeans or other oil crops by edible and medicinal fungi, and belongs to the technical field of fermentation. The method involves solid-state fermentation by inoculating edible and medicinal fungi such as i Ganoderma lucidum, Tremella aurantialba, Hericium erinaceus and | 2021-10-21 |
20210322498 | BITTER GANODERMA LUCIDUM SPORE POWDER AND PREPARATION METHOD THEREOF - Disclosed is a method for preparing bitter | 2021-10-21 |
20210322499 | MOXIBUSTION COMPOSITION COMPRISING HEMP FLOWER OR BIOMASS AND/OR CANNABIDIOL OIL - The present invention relates to a moxibustion composition, and particularly relates to a moxibustion composition comprising hemp biomass and/or cannabidiol oil. | 2021-10-21 |
20210322500 | METHOD FOR PRODUCING STABLE ACTINIDIA DELICIOSA POWDER WITH HIGH LEVEL BIOACTIVE ACTINIDIN ENZYME - A method for producing stable and bioavailable | 2021-10-21 |
20210322501 | COMPOSITION FOR PREVENTING, TREATING OR IMPROVING PROSTATE DISEASE CONTAINING ACANTHOPANAX SESSILIFLORUS, PHRAGMITES RHIZOME, AND PINUS DENSIFLORA EXTRACTS AS ACTIVE INGREDIENT - The present invention relates to a composition for preventing, treating or improving a prostate disease containing | 2021-10-21 |
20210322502 | PURIFIED XANTHOPHYLL COMPOSITION COMPRISING (TRANS,R,R)- LUTEIN AND(TRANS,R,R)- ZEAXANTHIN AND PROCESS FOR THE PREPARATION THEREOF - The invention relates to a purified xanthophyll composition comprising (trans,R R)-lutein and (trans,R,R)-zeaxanthin, which is comprised of more than 80% of total xanthophylls and a process for the preparation thereof. Purified xanthophyll composition is comprised of selective isomers such as at least 85% by weight of (trans,R,R)-lutein and at least 15% by weight of (trans,R,R)-zeaxanthin. The composition is prepared by process of extraction from two different plant sources using industrially viable process and purified by employing food grade polar and non-polar solvents. The invention relates to purified xanthophyll composition which is selectively free from (R,S)-zeaxanthin and is suitable for human consumption. | 2021-10-21 |
20210322503 | HERBAL FORMULATION FOR CONSTIPATION AND GASTRIC TROUBLES - The present invention discloses a herbal formulation for curing mild to chronic constipation, acidity and gastric troubles. The formulation comprises of Cassia angutifolia, Terminalia chebula, Carum copticum, and Sanchal. Further, the formulation is prepared using grinding, pulverization and mixing. Further, the formulation can be administered orally in the form of a tablet, capsule, powder or liquid. Additionally, the herbal formulation helps promote proper digestion, by regulating bowel movements of the body. | 2021-10-21 |
20210322504 | COMPOSITION FOR TREATING VITILIGO - A first embodiment of a composition for treating vitiligo includes | 2021-10-21 |
20210322506 | TREATING DRY EYE DISORDERS - This disclosure is related to compositions and methods for treating dry dye disorders. | 2021-10-21 |
20210322507 | GENOTYPE-DIRECTED LOCAL DELIVERY OF TARGETED THERAPEUTICS - Provided herein are pharmaceutical compositions for local administration of metabolic inhibitors, methods of locally administering such compositions, and rapid diagnostic methods for identifying mutant allele during the course of a surgical procedure. | 2021-10-21 |
20210322508 | PEPTIDES AND COMPOSITIONS FOR TARGETED TREATMENT AND IMAGING - The invention disclosed herein provides compositions and methods of treating cancer and other diseases related to activated immune cells using modulators of the TREM-1/DAP-12 signaling pathway. The compositions, including peptides and peptide variants, modulate TREM-1-mediated immunological response as standalone and combination-therapy treatment regimen. Further, methods are provided for predicting the efficacy of TREM-1 modulatory therapies in patients. In one embodiment, the present invention relates to targeted treatment, prevention and/or detection of cancer including but not limited to lung cancer including non-small cell lung cancer, pancreatic cancer, giant cell tumor of the tendon sheath, tenosynovial giant cell tumor, pigmented villonodular synovitis, cancer cachexia, etc., and other cancers associated with myeloid cell activation and recruitment. Additionally, the present invention relates to the targeted treatment, prevention and/or detection of scleroderma including but not limited to calcinosis, Raynaud's phenomenon, esophageal dysmotility, scleroderma, or telangiectasia syndrome (CREST). The invention further relates to personalized medical treatments. | 2021-10-21 |
20210322509 | Methods for Reducing Perinatal Morbidity and / or Mortality - A method for preventing or reducing the risk of perinatal or neonatal morbidity and mortality caused by antenatal inflammation in humans is described. This method is based on the administration of a compound of formula I or a pharmaceutically acceptable salt thereof: | 2021-10-21 |
20210322510 | OXYTOCIN IMPROVES TREATMENT OF OBSTRUCTIVE SLEEP APNEA - The present disclosure provides methods for treating obstructive sleep apnea (OSA) and OSA induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: OSA or OSA induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin. The disclosure further provides methods for improving sleep satisfaction in OSA patients by administering oxytocin. | 2021-10-21 |
20210322511 | METHODS AND COMPOSITIONS FOR TREATING A RESPIRATORY DISEASE - Provided herein are methods and compositions related to treating a respiratory disease and a method of making a lung surfactant composition. | 2021-10-21 |
20210322512 | CONFORMATIONALLY-SPECIFIC VIRAL IMMUNOGENS - The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine. | 2021-10-21 |
20210322513 | METHOD FOR DETECTING CANCER CELLS, REAGENT FOR INTRODUCING SUBSTANCE INTO CANCER CELLS, AND COMPOSITION FOR TREATING CANCER - As a technique for specifically detecting cancer cells, provided is a method for detecting cancer cells, including the steps of: bringing BC2LCN lectin into contact with a test sample; and determining the presence or absence or the amount of a sugar chain having a BC2LCN lectin binding activity in the test sample, in which the test sample is a body fluid sample of a test individual. | 2021-10-21 |
20210322514 | METHODS AND COMPOSITIONS FOR TREATING MYELOFIBROSIS - In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia). | 2021-10-21 |
20210322515 | METHODS FOR TREATING FIBROTIC CANCERS - In part, the disclosure relates to methods of treating fibrotic cancers by administering one or more Serum Amyloid Protein (SAP) agonists. In certain aspects, the method further comprises the conjoint administration of an anti-cancer therapeutic, e.g., a chemotherapeutic agent. In certain aspects, the disclosure relates to methods of treating myelofibrosis by administering an SAP agonist and optionally one or more anti-cancer therapeutic agents. | 2021-10-21 |
20210322516 | FUSION POLYPEPTIDES AND METHODS OF USE - The present disclosure relates to fusion polypeptides comprising fragments from a first and a second FGF family member, nucleic acids encoding the fusion polypeptides, vectors and host cells containing the same, and methods of making and using such compositions in the treatment of FGF-related diseases, disorders, and conditions. | 2021-10-21 |
20210322517 | BIODEGRADABLE DRUG DELIVERY COMPOSITION - The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. In some cases, the composition includes sucrose acetate isobutyrate, biodegradable polymer, hydrophobic solvent, and a complex comprising a counterion and beneficial agent, such as protein, peptide, nucleic acid, or small molecular weight compound. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition. | 2021-10-21 |
20210322518 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME - The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions. | 2021-10-21 |
20210322519 | PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOF - A pharmaceutical composition comprising a GHRH molecule or a pharmaceutically acceptable salt thereof is described, as well as uses thereof and a kit for preparing such a pharmaceutical composition. In an embodiment, GHRH molecule or pharmaceutically acceptable salt thereof is trans-3-hexenoyl-GHRH | 2021-10-21 |
20210322520 | METHODS OF MODULATING CORTICOSTEROID RESPONSE - The present disclosure is directed to methods of modulating corticosteroid responses in subjects in need thereof. | 2021-10-21 |
20210322521 | COMPOSITIONS AND METHODS FOR TREATING CORNEAL ENDOTHELIUM - Compositions of proteoglycans and core proteins thereof and related methods of treating subjects, e.g., patients, are described. The method may include applying a composition to an eye of a subject before, during, and/or after an intraocular medical procedure. The composition may comprise a proteoglycan or core protein thereof, such as decorin proteoglycan or decorin core protein, and a pharmaceutically-acceptable salt. The composition may be in the form of an aqueous solution, viscoelastic gel, or viscoelastic film, for example. Further methods are described that include treating donor corneal tissue with a composition comprising a proteoglycan or core protein thereof. The treated donor corneal tissue may be used as or in a corneal graft, such as during endothelial keratoplasty. | 2021-10-21 |
20210322522 | COMPOSITIONS AND METHOD FOR MANIPULATING PIM-1 ACTIVITY IN CIRCULATORY SYSTEM CELLS - The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart. | 2021-10-21 |
20210322523 | COMPOSITIONS FOR USE TO TREAT ADVANCED GLYCATION END PRODUCTS-DEPENDENT OCULAR DISEASES - The disclosure relates to the treatment of blindness due to age-related presbyopia, age-related macular degeneration (AMD), diabetic retinopathy (DR) and/or diabetic macular edema (DME) in a human or animal. Age-related presbyopia is the loss of accommodation in any individual more than 40-50 years old, currently treated by reading glasses. AMD is the most common cause of irreversible loss of sight in persons>65 years in the western world. At this time, no treatment is available for the dry form of AMD. The dry form of AMD is characterized by vision threatening Drüsen, which are (sub)retinal accumulations of advanced glycation end products (AGEs) and fluorophores. DR and DME are the most common cause of irreversible loss of sight in persons<65 years in the western world. Current therapies for age-related presbyopia, AMD, DR and DME are disappointing and do not prevent the evolution to vision impairment, atrophy or blindness. The disclosure specifically relates to the administration of fructosamine-3-kinase and its cofactor(s). This results in deglycation and inactivation of AGEs and fluorophores. | 2021-10-21 |
20210322524 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISRODERS - A method of inhibiting aberrant ATAD3A activation and/or oligomerization in mitochondria of a cell includes administering to the cell a therapeutic agent that inhibits binding or complexing of ATAD3A with Drp1 in the mitochondria of the cell. | 2021-10-21 |
20210322525 | SEQUENCE SPECIFIC ANTIMICROBIALS - Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both. | 2021-10-21 |
20210322526 | ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE - The present invention is direct to the treatment of Pompe disease by administration of an enzyme or nucleic acid encoding for said enzyme suitable for Enzyme Replacement Therapy for Pompe disease in combination with the administration of an antisense oligomeric compound that modulates the splicing of acid alpha-glucosidase (GAA) gene. | 2021-10-21 |
20210322527 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-10-21 |
20210322528 | PEPTIDES FROM NPSR1 - The present invention relates to novel peptides derived from Neuropeptide S Receptor (NPSR1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer. | 2021-10-21 |
20210322529 | CANCER VACCINES AND METHODS OF PRODUCING AND USING SAME - A method of vaccinating a subject is provided, where a cancer protective response is produced. A first vaccine comprises an adenovirus vector comprising at least one nucleic acid molecule that produces a cancer protective response is administered, followed by one or more second vaccines comprising an alphavirus replicon particle comprising RNA comprising or produced from the nucleic acid molecule. In an embodiment the cancer is prostate cancer. | 2021-10-21 |
20210322530 | COMPOSITION FOR PREVENTING OR TREATING MYCOPLASMA SYNOVIAE INFECTION - The present disclosure relates to a composition for preventing and treating | 2021-10-21 |
20210322531 | MUCOSAL VACCINE COMPOSITION FOR BOVINE MASTITIS - A mucosal vaccine composition for preventing bovine mastitis, comprising: an antigen derived from | 2021-10-21 |
20210322532 | BACTERIAL VACCINE COMPONENTS AND USES THEREOF - Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0442, based on the gene nomenclature from the | 2021-10-21 |
20210322533 | VACCINE FORMULATIONS COMPRISING PRESERVATIVE - The present invention relates to vaccine formulations comprising preservative systems. More particularly, the present invention relates to preservative systems for vaccine formulations which is free of thiomersal, and comprising 2-phenoxyethanol and at least one other preservative selected from m-cresol, benzyl alcohol, phenol and benzoic acid. | 2021-10-21 |
20210322534 | METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3 - The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same. | 2021-10-21 |
20210322535 | VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSES - Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier. | 2021-10-21 |
20210322536 | Boosting Immunogenicity of Vaccines Using Saponins and Agonists of the Intracellular Stimulator of Interferon Genes Pathway - This disclosure relates to boosting the immunogenicity of vaccines using an adjuvant combination comprising a saponin and an agonist of the intracellular stimulator of interferon genes pathway. In certain embodiments, the vaccine comprises an inactivated virus, attenuated virus, virus protein, virus like particle, or virosome. In certain embodiments, the human subject is of advanced age or elderly. In certain embodiments, the viral vaccine is an influenza vaccine. | 2021-10-21 |
20210322537 | Method For Preparation of Quick Dissolving Thin Films Containing Bioactive Material With Enhanced Thermal Stability - Methods for the preparation of polymeric films which encase and preserve bioactive agents. In particular, the invention is directed to the preparation of oral thin films containing bioactive proteins or viruses. For example, methods and compositions are disclosed for preservation of rotavirus and antibodies in thin dry films. | 2021-10-21 |
20210322538 | VACCINE TO PATHOGENIC IMMUNE ACTIVATION CELLS DURING INFECTIONS - A method for preventing an infectious disease in a subject in need thereof. In particular the method includes the administration of a combination, pharmaceutical combination, medicament or kit-of-parts including a first part including a CD8 vaccine specific for at least one infectious disease-related antigen, optionally a second part including an interferon alpha blocking agent, and a third part including a type III interferon and/or an agent stimulating the production of type III interferon. | 2021-10-21 |
20210322539 | Cure to new viruses and other diseases that do not have current cure - New approach to enable to find quick and efficient cure to new viruses and other diseases that do not have current cure. To avoid epidemic and save lives of people | 2021-10-21 |
20210322540 | ORAL VACCINES EXPRESSED IN YEAST FOR COVID-19 - Nucleic acid constructs for heterologous expression of a SARS-CoV-2 antigen on the surface of a yeast cell and related polypeptides, recombinant yeast cells, vaccine compositions, oral dosage formulations, and methods of inducing antigen-specific immune response to SARS-CoV-2. | 2021-10-21 |
20210322541 | CORONAVIRUS VACCINE - Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection. | 2021-10-21 |
20210322542 | VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE - Provided herein is a method for preventing an infectious disease caused by a Coronaviridae virus with a poliomyelitis vaccine. Also provided herein is a method of inducing a protective immune response against a Coronaviridae virus with a poliomyelitis vaccine. | 2021-10-21 |
20210322543 | EGG ALLERGY ANTIGEN - The present invention provides a novel antigen for an egg allergy, a method for diagnosing an egg allergy and a kit for diagnosing an egg allergy, a pharmaceutical composition comprising the antigen, an egg, a processed product of an egg, or a bird which lays or has hatched from the egg in which the antigen is eliminated or reduced, a method for producing a processed product of an egg in which the antigen is eliminated or reduced, and a tester for determining the presence or absence of an egg antigen in an object of interest. | 2021-10-21 |
20210322544 | VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLE AS ADJUVANT - The present disclosure provides vaccine compositions and methods for inducing a systemic immune response and a mucosal immune response, wherein the vaccine compositions comprise an antigen and a hepatitis B core virus-like particle (HBc VLP) as adjuvant. The vaccine compositions are suitable for administration to the mucosa surface of subject, and are effective in eliciting a protective immune response against infection. | 2021-10-21 |
20210322545 | SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER - The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory or immunomodulatory compound or oncolytic virus. | 2021-10-21 |
20210322546 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST - The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody. | 2021-10-21 |
20210322547 | METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST - Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSF | 2021-10-21 |
20210322548 | METHODS AND COMPOSITIONS RELATING TO TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGFβ1, TGFβ3, and/or GDF-15. | 2021-10-21 |
20210322549 | Stable Aqueous Formulations of Natalizumab - Described herein is a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of natalizumab (optionally not subjected to prior lyophilization), a buffer effective to maintain the pH in the range from about 4.0 to about 7.0; and optionally, one or more surfactant{s), one or more amino acid(s), one or more sugar(s), one or more polyol(s), one or more chelating agent(s) (one or more polymer(s), one or more other stabilizing agent(s); and methods for making such a formulation; and methods of using such a formulation. | 2021-10-21 |
20210322550 | ANTIBODY-CONTAINING FORMULATIONS - In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose. | 2021-10-21 |
20210322551 | LIQUID PHARMACEUTICAL COMPOSITION - The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug. | 2021-10-21 |
20210322552 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-10-21 |
20210322553 | ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS - Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients. | 2021-10-21 |
20210322554 | A COMPOSITION COMPRISING A PROTEIN AND A POLYALKOXY FATTY ACYL SURFACTANT - A composition comprising a protein and a polyalkoxy fatty acyl surfactant of general formula I | 2021-10-21 |
20210322555 | NITRIC OXIDE RELEASING PHARMACEUTICAL COMPOSITIONS - The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same. | 2021-10-21 |
20210322556 | NON-IONIC BLOCK COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROM - There are provided PVP-PLA block copolymers as defined in Formula (I): I wherein, x is an initiator alcohol having a boiling point greater than 145° C., n is, on average, from 20 and 40, and m is, on average, from 10 and 40, wherein the block copolymers have a number average molecular weight (M | 2021-10-21 |
20210322557 | HYDROLYTICALLY DEGRADABLE POLYSACCHARIDE HYDROGELS - Provided are polysaccharide compositions capable of controllable hydrolytic degradation and suitable for controlled release of therapeutic agents. Also provided are methods for synthesizing such compositions and a variety of applications in which the compositions may be used. | 2021-10-21 |